CLINICAL_TRIALS
trial_result
· 2023-02-01
Clinical Trial Update: Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) [Phase 3]
Summary
Phase 3 trial of masitinib in first-line treatment for gastrointestinal stromal tumors was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AB Science | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: TERMINATED